GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Slideshows|September 14, 2016
ADHD Research Update: September 2016
Author(s)Mark L. Fuerst
Three new studies in children with ADHD reveal an association with seizures, the benefits of after-school exercise, and brain changes linked to treatment.
Advertisement
References:
1. Bertelsen EN, Larsen JT, Petersen L, et al.
2. Bustamante EE, Davis CL, Frazier SL, et al.
3. Schrantee A, Tamminga HGH, Bouziane C, et al.
Advertisement
Related to this article
A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Schizophrenia: A Telltale of the Brain’s Complexity
3
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
4
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
5